Mr. Michael R. Minogue is the Chief Executive Officer, President and Chairman of Abiomed Inc. (NASDAQ: ABMD). Since joining in 2004, Mr. Minogue transitioned the corporate mission to heart muscle recovery through creation of breakthrough percutaneous, heart support technologies. This included the acquisition and development of new technologies such as Impella®, the world’s smallest heart pump. Abiomed, a public company (ABMD) with revenues over $400 million, employs approximately 800 people with facilities in Danvers, Massachusetts, Aachen and Berlin, Germany and Tokyo, Japan.
During Mr. Minogue’s tenure, Abiomed has grown approximately 1,800% in revenue, 2,000% in market capitalization (~$4 billion) and is GAAP profitable with no debt and solid balance sheet. Abiomed has earned over 30 global regulatory approvals on new products in the United States, Europe, Japan, China and other countries.
Mr. Minogue currently represents the medical device industry by serving: on the executive board of directors for AdvaMed, and as Chairman of Medical Device Industry Consortium (MDIC), a public private partnership with the industry, government and non-profits. Mr. Minogue formerly served on the board of LifeCell Corporation (LIFC) before it was acquired in 2008. Mr. Minogue is one of the co-founders and Chairman of the MedTech and BioTech Veterans Program (MVP) (www.mvpvets.org), a 501(c)(3) non-profit organization that helps military veterans network with industry mentors to discover career opportunities in the life sciences industries.
Mr. Minogue joined Abiomed from General Electric Healthcare, where he holds three patents and spent 11 years developing expertise in sales, marketing, product development and software/service operations around diagnostic imaging and treatment of cancer and cardiovascular disease. Earlier in his life, Mr. Minogue served as an Infantry officer in the U.S. Army, which included multiple distinctions including Airborne, RANGER, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his MBA from the University of Chicago.
Mr. Minogue is married with five children and enjoys reading, mentoring, running, coaching, skiing and playing sports.
Dr. W. Gerald Austen, M.D., has served as a Director of the Company since 1985. Since 1974 he has been the Edward D. Churchill Professor of Surgery at Harvard Medical School and at Massachusetts General Hospital. From 1969 to 1997, Dr. Austen was Chief of the Surgical Services at Massachusetts General Hospital. Dr. Austen is the former President of the American College of Surgeons, the American Association for Thoracic Surgery, the American Surgical Association and the Massachusetts and American Heart Associations. Dr. Austen is a member of the Institute of Medicine of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, an Honorary Trustee of the Massachusetts General Hospital, a life member Emeritus of the Corporation of the Massachusetts Institute of Technology and Chairman Emeritus of the Board of Trustees of the John S. and James L. Knight Foundation.
Ms. Dorothy E. Puhy has served as a Director of the Company and chair of its Audit Committee since 2003. Ms. Puhy is currently Executive Vice President, Chief Operating Officer for the Dana-Farber Cancer Institute (“Dana-Farber”). Previously, beginning in 1994, Ms. Puhy served as Dana-Farber’s Chief Financial Officer and Assistant Treasurer. From 1985 to 1994 Ms. Puhy held various financial positions at the New England Medical Center Hospitals, Inc., including Chief Financial Officer from 1989 to 1994.
Mr. Martin P. Sutter is Founder and Managing Director of Essex Woodlands, one of the oldest and largest life sciences/healthcare focused venture capital and growth equity investment firms. Essex Woodlands manages over $2.5 billion of capital, and currently is investing Essex Woodlands Fund VIII, a $900 million fund focused on growth equity and select venture capital investments. Essex Woodlands has offices in New York, London, Palo Alto, Houston and Shanghai. Mr. Sutter has founded a number of successful healthcare and biotechnology companies originating from institutions of the world renowned Texas Medical Center. He has served on numerous past Boards of Directors of public and private companies including ATS Medical which was acquired by Medtronic, Inc., BioForm Medical which was acquired by Merz GmbH & Co KGaA, Lifecell which was acquired by Kinetic Concepts, Inc., St. Francis Medical which was acquired by Kyphon, Inc./Medtronic, Inc., Confluent Surgical which was acquired by Tyco International and Rinat Neurosciences which was acquired by Pfizer, Inc. He currently serves on the Board of Directors of QSpex Technologies and Bioventus.
Mr. Henri A. Termeer served as Chairman, President and Chief Executive Officer of Genzyme Corporation for nearly three decades. Mr. Termeer was appointed President of Genzyme in 1983, two years after the company’s founding. He became its Chief Executive Officer in 1985 and Chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. Mr. Termeer is a Board member of Massachusetts Institute of Technology Corporation and serves on its Executive Committee, a director of Massachusetts General Hospital, Board member of Partners HealthCare, a member of the Board of Fellows of Harvard Medical School and on the Board of the Biotechnology Industry Organization (BIO). He also serves on the Boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., Medical Simulation Corporation and Moderna Therapeutics. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors and he is a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. Mr. Termeer is also Chairman Emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. He was elected a Fellow of the American Academy of Arts and Sciences in 1999. Mr. Termeer was Chairman of the Federal Reserve Bank of Boston’s Board of Directors from 2010-2011 and served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia. Mr. Termeer has been recognized by several highly regarded organizations for his contributions to the healthcare and entrepreneurial field.
Mr. Paul G. Thomas served as Founder, Chief Executive Officer and President of Roka Bioscience, a molecular diagnostics company focused on food safety applications, from September 2009 until his retirement in January 2017. Mr. Thomas previously served as Chairman, Chief Executive Officer and President of LifeCell Corporation, a publicly traded regenerative medicine company, from 1998 until it was acquired by KCI in 2008 in a transaction valued at $1.8 billion. Mr. Thomas previously held various senior positions, including President of the Pharmaceutical Products Division, during his tenure of 15 years with Ohmeda, a world leader in inhalation anesthetics and acute care pharmaceuticals. Mr. Thomas currently serves on the Boards of Abiomed (NASDAQ:ABMD), RTI Surgical (NASDAQ:RTIX) and Roka Bioscience (NASDAQ: ROKA). Mr. Thomas received his M.B.A. degree from Columbia University Graduate School of Business and completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science. He received his B.S. degree in Chemistry from St. Michael’s College in Vermont.
Eric Rose is an academic physician and entrepreneur with interests in drug discovery, biodefense, clinical evaluative research and health policy. Since 2007 he is the Executive Vice President for Life Sciences at MacAndrews and Forbes and CEO of Siga Technologies, Inc., a developer of an anti-viral drug directed at potential agents of bioterror. From 2007 through 2011, he served on the National Biodefense Scientific Board which advises the HHS Secretary on biodefense, influenza, and emerging diseases. From 2008 through 2012, he chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine. From 1994 through 2007, he served as Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons, where he held a distinguished professorship. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984. Dr. Rose received both his undergraduate and medical degrees from Columbia University.
Jeannine Rivet is executive vice president of UnitedHealth Group, the most diversified healthcare company in the U.S. In her role, Ms. Rivet works with and on behalf of all business segments in areas focused on strategic business relationships, customer relations, and clinical advancement. Previous roles at UnitedHealth Group include Chief Executive Officer of UnitedHealthcare, Chief Executive Officer of Ingenix and Chief Executive Officer of Optum. Ms. Rivet is a driving force in challenging the industry to enhance health and well-being through information, collaboration and advancement of optimal health care. Ms. Rivet is on the executive leadership team of UnitedHealth Group and on numerous industry leadership boards and councils, as well as a mentor to women in business. She has been recognized by AAHP, Boston University School of Public Health, Fortune magazine, Girl Scouts of Minnesota and Wisconsin River Valleys, Minneapolis/St. Paul Business Journal and Minnesota’s City Business and was inducted as a fellow into the American Academy of Nursing. Ms. Rivet received her master’s degree in Public Health from Boston University. She also holds a bachelor’s degree in nursing from Boston College and was a registered nurse for several years prior to entering the managed care business.
Chris Van Gorder has been President and Chief Executive Officer of Scripps Health since 2000, where he has been instrumental in positioning Scripps among the nation’s foremost health care institutions. At Scripps Health, Mr. Van Gorder oversees all functions of the integrated health system that has 15,000 employees and 2,600 affiliated physicians, including its five acute-care hospital campuses, dozens of outpatient centers throughout San Diego County, and a regional home health service and hospice. In March 2006, California’s governor appointed Mr. Van Gorder, a former police officer, to the California Commission on Emergency Medical Services (EMSA) where he served two terms. In January 2007, U.S. Secretary of State Condoleezza Rice reappointed Mr. Van Gorder to the U.S. Commission for the United Nations Educational, Scientific and Cultural Organization (UNESCO). He is a Clinical Professor of health practice at the University of Southern California (USC) Price School of Public Policy, where he also serves on the Board of Councilors. Mr. Van Gorder received his master’s degree in public administration/health services administration at the University of Southern California, completed the Wharton CEO Program at the University of Pennsylvania and earned his bachelor’s degree from California State University, Los Angeles.